NASDAQ:CMTA - Clementia Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $26.35 0.00 (0.00 %) (As of 04/17/2019)Previous Close$26.35Today's Range$26.28 - $26.6952-Week Range$8.10 - $26.73Volume716,706 shsAverage Volume145,059 shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/ABeta0.64 ProfileAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada. Receive CMTA News and Ratings via Email Sign-up to receive the latest news and ratings for CMTA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMTA Previous Symbol CUSIPN/A CIK1647320 Webhttp://www.clementiapharma.com/ Phone514-940-3600Debt Debt-to-Equity RatioN/A Current Ratio14.03 Quick Ratio14.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.18 per share Price / Book5.09Profitability EPS (Most Recent Fiscal Year)($7.93) Net Income$-58,130,000.00 Net MarginsN/A Return on Equity-44.73% Return on Assets-41.66%Miscellaneous Employees30 Outstanding Shares38,060,000Market Cap$1.00 billion Next Earnings DateN/A OptionableNot Optionable Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions What is Clementia Pharmaceuticals' stock symbol? Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA." How were Clementia Pharmaceuticals' earnings last quarter? Clementia Pharmaceuticals Inc (NASDAQ:CMTA) posted its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.04. View Clementia Pharmaceuticals' Earnings History. What price target have analysts set for CMTA? 6 Wall Street analysts have issued 12-month price objectives for Clementia Pharmaceuticals' stock. Their predictions range from $16.00 to $27.00. On average, they anticipate Clementia Pharmaceuticals' stock price to reach $24.20 in the next year. This suggests that the stock has a possible downside of 8.2%. View Analyst Price Targets for Clementia Pharmaceuticals. What is the consensus analysts' recommendation for Clementia Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clementia Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Clementia Pharmaceuticals. Has Clementia Pharmaceuticals been receiving favorable news coverage? Press coverage about CMTA stock has been trending positive on Saturday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Clementia Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. Who are some of Clementia Pharmaceuticals' key competitors? Some companies that are related to Clementia Pharmaceuticals include Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Blueprint Medicines (BPMC), United Therapeutics (UTHR), Evotec (EVTCY), ACADIA Pharmaceuticals (ACAD), HUTCHISON CHINA/S (HCM), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Mirati Therapeutics (MRTX) and Reata Pharmaceuticals (RETA). What other stocks do shareholders of Clementia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clementia Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Madrigal Pharmaceuticals (MDGL), Rigel Pharmaceuticals (RIGL), JPMorgan Chase & Co. (JPM), Exelixis (EXEL), Eyepoint Pharmaceuticals (EYPT), Amicus Therapeutics (FOLD), Myokardia (MYOK), Omeros (OMER) and Spark Therapeutics (ONCE). Who are Clementia Pharmaceuticals' key executives? Clementia Pharmaceuticals' management team includes the folowing people: Dr. Clarissa Desjardins, Founder, Pres, CEO & Director (Age 52)Dr. Donna Roy Grogan M.D., Chief Medical Officer (Age 62)Mr. Jeffrey Packman, Chief Devel. Officer (Age 52)Mr. Steve Forte, CFO & Corp. Sec. (Age 40)Mr. Joseph Andrew Walewicz, Exec. VP of Bus. & Corp. Devel. (Age 50) When did Clementia Pharmaceuticals IPO? (CMTA) raised $101 million in an initial public offering on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at $13.00-$15.00 per share. Morgan Stanley and Leerink Partners acted as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers. Who are Clementia Pharmaceuticals' major shareholders? Clementia Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (5.39%), JPMorgan Chase & Co. (4.20%), Wellington Management Group LLP (2.20%), Opaleye Management Inc. (1.05%), Water Island Capital LLC (1.01%) and Water Island Capital LLC (1.01%). Which institutional investors are selling Clementia Pharmaceuticals stock? CMTA stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Federated Investors Inc. PA, Janus Henderson Group PLC and Morgan Stanley. Which institutional investors are buying Clementia Pharmaceuticals stock? CMTA stock was bought by a variety of institutional investors in the last quarter, including Water Island Capital LLC, Water Island Capital LLC, IndexIQ Advisors LLC, Gabelli Funds LLC, Opaleye Management Inc., Elo Mutual Pension Insurance Co, GABELLI & Co INVESTMENT ADVISERS INC. and JPMorgan Chase & Co.. How do I buy shares of Clementia Pharmaceuticals? Shares of CMTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Clementia Pharmaceuticals' stock price today? One share of CMTA stock can currently be purchased for approximately $26.35. How big of a company is Clementia Pharmaceuticals? Clementia Pharmaceuticals has a market capitalization of $1.00 billion. The company earns $-58,130,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe. What is Clementia Pharmaceuticals' official website? The official website for Clementia Pharmaceuticals is http://www.clementiapharma.com/. How can I contact Clementia Pharmaceuticals? Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected] MarketBeat Community Rating for Clementia Pharmaceuticals (NASDAQ CMTA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 149 (Vote Outperform)Underperform Votes: 162 (Vote Underperform)Total Votes: 311MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CMTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: Hedge Funds Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.